Jordan N Kohn1, Matthew Shane Loop2, Julie J Kim-Chang3, Patricia A Garvie4, John W Sleasman3, Bernard Fischer3, H Jonathon Rendina5, Steven Paul Woods6, Sharon L Nichols7, Suzi Hong1,8. 1. Department of Psychiatry, University of California San Diego, La Jolla, CA. 2. Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina Chapel Hill, Chapel Hill, NC. 3. Division of Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, NC. 4. Children's Diagnostic and Treatment Center, Fort Lauderdale, FL. 5. Department of Psychology, Hunter College, CUNY, New York, NY. 6. Department of Psychology, University of Houston, Houston, TX. 7. Department of Neurosciences, University of California San Diego, La Jolla, CA; and. 8. Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA.
Abstract
BACKGROUND: Depression and neurocognitive impairment are highly prevalent among persons living with HIV and associated with poorer clinical outcomes; however, longitudinal studies of depression-neurocognition relationships in youth living with HIV (YLWH), and the role of antiretroviral therapy (ART), are lacking. This study tested whether (1) depressive symptomatology, across somatic, cognitive, and affective symptom domains, improved with ART and (2) more severe depressive symptoms at baseline were associated with poorer neurocognitive function and poorer HIV suppression. SETTING: Data were collected from 181 YLWH (18-24 years) who were treatment-naive, a subset of whom (n = 116) initiated ART. METHODS: Participants were categorized into elevated (DS) or nonelevated (non-DS) depressive symptom groups at entry (Beck Depression Inventory-II ≥14) and followed for 36 months. Neurocognition (5-domain battery) and depressive symptoms were repeatedly assessed. Longitudinal models examined depressive symptomatology, neurocognition, and odds of HIV nonsuppression by group. RESULTS: Greater improvements in depressive symptoms were observed in the DS group over 36 months [beta = -0.14, (-0.24 to -0.03)], particularly within cognitive and affective domains. Verbal learning performance increased in the DS group [beta = 0.13, (0.01 to 0.24)], whereas psychomotor function improved somewhat in the non-DS group [beta = -0.10, (-0.22 to 0.00)]. Adjusted for ART adherence, odds of HIV nonsuppression did not significantly differ by group [odds ratio = 0.22, (0.04 to 1.23)]; however, greater somatic symptoms at study entry were associated with an increased risk of nonsuppression over time [odds ratio = 2.33 (1.07 to 5.68)]. CONCLUSION: Depressive symptoms were associated with differential neurocognitive trajectories, and somatic depressive symptoms at baseline may predict poorer subsequent HIV suppression. Identifying and treating depressive symptoms at ART initiation may benefit neurocognitive and clinical outcomes in YLWH.
BACKGROUND: Depression and neurocognitive impairment are highly prevalent among persons living with HIV and associated with poorer clinical outcomes; however, longitudinal studies of depression-neurocognition relationships in youth living with HIV (YLWH), and the role of antiretroviral therapy (ART), are lacking. This study tested whether (1) depressive symptomatology, across somatic, cognitive, and affective symptom domains, improved with ART and (2) more severe depressive symptoms at baseline were associated with poorer neurocognitive function and poorer HIV suppression. SETTING: Data were collected from 181 YLWH (18-24 years) who were treatment-naive, a subset of whom (n = 116) initiated ART. METHODS: Participants were categorized into elevated (DS) or nonelevated (non-DS) depressive symptom groups at entry (Beck Depression Inventory-II ≥14) and followed for 36 months. Neurocognition (5-domain battery) and depressive symptoms were repeatedly assessed. Longitudinal models examined depressive symptomatology, neurocognition, and odds of HIV nonsuppression by group. RESULTS: Greater improvements in depressive symptoms were observed in the DS group over 36 months [beta = -0.14, (-0.24 to -0.03)], particularly within cognitive and affective domains. Verbal learning performance increased in the DS group [beta = 0.13, (0.01 to 0.24)], whereas psychomotor function improved somewhat in the non-DS group [beta = -0.10, (-0.22 to 0.00)]. Adjusted for ART adherence, odds of HIV nonsuppression did not significantly differ by group [odds ratio = 0.22, (0.04 to 1.23)]; however, greater somatic symptoms at study entry were associated with an increased risk of nonsuppression over time [odds ratio = 2.33 (1.07 to 5.68)]. CONCLUSION: Depressive symptoms were associated with differential neurocognitive trajectories, and somatic depressive symptoms at baseline may predict poorer subsequent HIV suppression. Identifying and treating depressive symptoms at ART initiation may benefit neurocognitive and clinical outcomes in YLWH.
Authors: A Norcini Pala; P Steca; R Bagrodia; L Helpman; V Colangeli; P Viale; M L Wainberg Journal: Brain Behav Immun Date: 2016-02-13 Impact factor: 7.217
Authors: Caitlin Wei-Ming Watson; Emily W Paolillo; Erin E Morgan; Anya Umlauf; Erin E Sundermann; Ronald J Ellis; Scott Letendre; Thomas D Marcotte; Robert K Heaton; Igor Grant Journal: J Acquir Immune Defic Syndr Date: 2020-01-01 Impact factor: 3.771
Authors: Emily W Paolillo; Elizabeth C Pasipanodya; Raeanne C Moore; Brian W Pence; Joseph Hampton Atkinson; David J Grelotti; Igor Grant; Robert K Heaton; David J Moore Journal: J Acquir Immune Defic Syndr Date: 2020-07-01 Impact factor: 3.731
Authors: Lewis J Haddow; Rosanna Laverick; Marina Daskalopoulou; Jeffrey McDonnell; Fiona C Lampe; Richard Gilson; Andrew Speakman; Andrea Antinori; Pietro Balestra; Tina Bruun; Jan Gerstoft; Lars Nielsen; Anna Vassilenko; Simon Collins; Alison J Rodger Journal: AIDS Behav Date: 2018-05
Authors: Bin Tang; A C Collier; S Morgello; D Cookson; N Sacktor; Ronald J Ellis; Christina M Marra; David B Clifford; Benjamin B Gelman; Jessica Robinson-Papp; J Allen McCutchan; Scott Letendre; Robert K Heaton; Igor Grant Journal: Brain Behav Immun Health Date: 2022-03-10